ZBTB1 and T-cell non-Hodgkin lymphoma: Scholars have successfully constructed a Zbtb1 gene-knockout EL4 cell line using CRISPR-Cas9 technology and screened for differentially expressed microRNAs and circRNAs in normal and Zbtb1-deficient EL4 cell lines, providing potential targets for drug development and the clinical treatment of T-cell lymphoma [96].